【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，用於老年人時須謹慎使用(監測血鈉值)。

高血壓 (diuretics) 利尿劑 (loop diuretics) Acute pulmonary edema; Edema; Hypertension

Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and proximal and distal renal tubules, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium

Bioavailability:Oral solution: 50% Half-life elimination: Normal renal function: 0.5 to 2 hours; End-stage renal disease (ESRD): 9 hours Metabolism: Minimally hepatic Excretion: Urine (Oral: 50%, IV: 80%) within 24 hours; feces (as unchanged drug); nonrenal clearance prolonged in renal impairment

Anuria History of hypersensitivity to furosemide

C

Furosemide is present in breast milk; maternal use may suppress lactation. The manufacturer recommends that caution be used if administered to a breastfeeding woman.

Endocrine metabolic: Hyperuricemia (40%), Hypomagnesemia Gastrointestinal: Loss of appetite Renal: Spasm of bladder

Initial 2 mg/kg/dose increased in increments of 1 to 2 mg/kg/dose with each succeeding dose at intervals of 6 to 8 hours until a satisfactory response is achieved; maximum 6 mg/kg/dose

Children and Adolescents 1 to 17 years: Initial 0.5-2 mg/kg/dose once or twice daily; maximum 6 mg/kg/dose

Do not store above 25 °C; away from direct light